Use of octreotide in the treatment of chylopericardium.
Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.
Szabados
Eszter
E
Division of Cardiology, First Department of Medicine, University of Pecs, Pecs, Hungary. eszter.szabados@aok.pte.hu
Toth
Kalman
K
Mezosi
Emese
E
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010289:Parenteral Nutrition, Total; D010490:Pericardial Effusion / Q000188:drug therapy* / Q000628:therapy; D017211:Treatment Failure
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide